



AMENDMENTS TO THE CLAIMS

1. (Previously Presented) A compound represented by the following formula:




wherein



of formula I represents a 2'-deoxyribonucleoside or its N-protected derivative, the substituent $-O-(R_1)Si(R_2)-(C_6H_3R_6)-(CH_2)_n-O-P(OR_3)N(R_4)(R_5)$ is attached at the 3' position of the sugar moiety of the nucleoside substituent; each of R_1 , R_2 , R_4 and R_5 is an alkyl or optionally substituted aryl group, wherein the optionally substituted aryl group has a substituent selected from the group consisting of C_{1-5} alkyl, nitro, cyano, halo and methoxyl; R_3 is a protecting group; R_6 substituent of the benzene ring $-(C_6H_3R_6)-$ is selected from the group consisting of H, C_{1-4} alkyl, halo, nitro, cyano and methoxyl; R_7 is H or 4,4'-dimethoxytrityl; and n is an integer of from 1 to 5.


2. (Previously Presented) The compound according to Claim 1 wherein R_1 and R_2 are independently a C_{1-5} alkyl.
3. (Previously Presented) The compound according to Claim 1 wherein R_1 and R_2 are independently substituted aryl.

4. (Previously Presented) The compound according to any one of Claims 1 to 3 wherein the protecting group R_3 is 2-cyanoethyl, 4-nitrophenylethyl, N-(trifluoroacetyl)aminobutyl, or 4-[N-methyl-N-(2,2,2-trifluoroacetyl)amino]butyl.
5. (Previously Presented) The compound according to Claim 4 wherein the protecting group R_3 is 2-cyanoethyl.
6. (Previously Presented) The compound according to Claim 1 wherein each of R_4 and R_5 is independently C_{1-4} alkyl, benzyl, phenyl, or naphthyl.
7. (Previously Presented) The compound according to Claim 1 wherein each of R_4 and R_5 is independently isopropyl.
8. (Cancelled)
9. (Previously Presented) The compound according to Claim 1 wherein R_6 is selected from the group consisting of C_{1-4} alkyl, halo, nitro, cyano and methoxy.
10. (Previously Presented) A compound having the structure




wherein DMTr is 4,4'-dimethoxytrityl.

11. (Previously Presented) A compound having the structure



wherein DMTr is 4,4'-dimethoxytrityl.

12. (Previously Presented) A solid-phase support having a 3'-end nucleoside unit introduced thereon as represented by formula II:



wherein
 of formula II represents a 2'-deoxyribonucleoside or its N-protected derivative, the substituent $-O-(R_1)Si(R_2)-(C_6H_5R_6)-(CH_2)_n-O-P(OR_3)XO-(CH_2)_n$ is attached at the 3' position of the sugar moiety of the nucleoside substituent; each of R_1 and R_2 is an alkyl or optionally substituted aryl group, wherein the optionally substituted aryl group has a substituent selected from the group consisting of C_{1-4} alkyl, nitro, cyano, halo and methoxy; R_3 is a protecting group; X is S or O; R_7 is H or 4,4'-dimethoxytrityl; each n is an integer of from 1 to 5; and the solid-phase support has hydroxyl groups on its surface.

13. (Previously Presented) The solid-phase support according to Claim 12 having the 3'-end nucleoside units present at a ratio of 20-30 $\mu\text{mol/g}$.
14. (Cancelled)
15. (Cancelled)
16. (Cancelled)
17. (Previously Presented) The solid-phase support of claim 12, wherein the solid-phase support is a highly cross-linked polystyrene (HCP).
18. (Cancelled)
19. (Cancelled)